Publications & Reports

It is time to broaden community dissemination of cognitive-behavioral therapy for substance use disorders: Charting pathways to ascend the remaining mountainside.
Hartzler B.
Clinical Psychology: Science and Practice 2023; 30(2):147-149.

Cannabis Research Report, 2021-2023.
Carlini B, Garrett S, Kellum L, Nims L.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, August 2023.

The Status of Medications for Opioid Use Disorder (MOUD) Provision in Washington State Jails, 2021.
Owens M, Borges A, McGrath J, Stern MF.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2023.

“That line just kept moving”: Motivations and experiences of people who use methamphetamine.
Fockele CE, Morse SC, van Draanen J, Leyde S, Banta-Green C, Huynh LH, Zatzick A, Whiteside LK.
Western Journal of Emergency Medicine 2023;24(2):218-227.

Overview and Perspectives of Syringe Services Programs in Washington State.
Kingston S. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, February 2023.

“Like it was just everyday business”: A qualitative study of pharmacy-based naloxone and syringe customer experience.
Gray M, Shin SS, Silcox J, Flores D, Bolivar D, Irwin AN, Floyd AS, Bratberg J, Boggis JS, Hartung DM, Green TC.
Journal of the American Pharmacists Association 2023;63(3):838-846.

Community implementation of contingency management to address stimulant use.
Hartzler B, Gray K, Marx M, Kirk-Lewis K, Payne-Smith, McIlveen JW.
Journal of Substance Use and Addiction Treatment 2023;151:208941.

Overdose Deaths Involving Pharmaceutical Opioids in Washington State from 2010-2021.
Banta-Green C & Williams J.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, University of Washington, November 2022.

Readiness of community pharmacies to implement an opioid safety intervention.
Floyd AS, Silcox J, Cousin E, Irwin AN, Gray M, Bolivar D, Bratberg J, Arnold J, Al-jammali Z, Hansen RN, Hartung DM, Green TC.
Journal of the American Pharmacies Association 2023;63:275-283.

Virtual training is more cost-effective than in-person training for preparing staff to implement contingency management.
Hartzler B, Hinde J, Land S, et al.
Journal of Technology in Behavioral Science 2023;8:255-264.

Cannabis-only use in the USA: Prevalence, demographics, use patterns, and health indicators.
Carlini BH, Schauer GL.
Journal of Cannabis Research 2022;4:39.

The Community-Based Medication-First program for opioid use disorder: A hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
Banta-Green CJ, Owens MD, Williams JR, Sears JM, Floyd AS, Williams-Gilbert W, Kingston S.
Addiction Science & Clinical Practice 2022;17:34.

A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients’ sexual risk behavior.
Hatch MA, Wells EA, Masters T, Beadnell B, Harwick R, Wright L, Peavy M, Ricardo-Bulis E, Wiest K, Shriver C, Baer, JS.
Journal of Substance Abuse Treatment 2022; 140:108826.

Unmet Needs, Complex Motivations, and Care for People Using Fentanyl in Washington State: A Qualitative Study.
Winstead T, Newman A, Maroon E, Banta-Green C.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2023.

Reducing racial/ethnic disparities with a three-year case management program for mothers with problematic prenatal substance use, Washington State, 2006-2017.
Stoner SA, Graham JC, Grant TM.
BMC Public Health 2023 (in press).

Washington State HCA report to the legislature. High THC policy | Final report: Exploring policy solutions to address public health challenges of high THC products. Engrossed Substitute Senate Bill 5092; Section 215(55); Chapter 334; Laws of 2021.
Washington State Health Care Authority (HCA) & University of Washington Addictions, Drug & Alcohol Institute (ADAI). 
Olympia, WA; Washington State Health Care Authority, December 2022.

How should policy makers regulate the tetrahydrocannabinol content of cannabis products in a legal market? [opinion]
Hall W, Leung J, Carlini BH.
Addiction 2023;118(6):998-1003.

Cannabis and nicotine co-use among primary care patients in a state with legal cannabis access.
McClure EA, Hamilton L, Schauer GL, Matson TE, Lapham GT.
Addictive Behaviors 2023;140:107621.

Perspectives on medication treatment for opioid use disorder in adolescents: Results from a provider learning series.
Peavy KM, Adwell A, Owens MD, Banta-Green CJ.
Substance Use & Misuse 2023;58(1):160-162.

Home cannabis cultivation in the United States and differences by state-level policy, 2019-2020.
Wadsworth E, Schauer GL, Hammond D.
American Journal on Drug and Alcohol Abuse 2022; 48(6):701-711.

A trauma-informed parenting intervention model for mothers parenting young children during residential treatment for substance use disorder.
Jirkowic T, Graham CJ, Grant T.
Occupational Therapy in Mental Health 2023;39(2):156-183.

Behavioral healthcare organizations’ experiences related to use of telehealth as a result of the COVID-19 pandemic: an exploratory study.
Kisicki A, Becker S, Chaple M, Gustafson DH, Hartzler BJ, et al.
BMC Health Services Research 2022;22:775.

Discrimination, acculturative stress, alcohol use and their associations with alcohol-related consequences among Latino immigrant men.
Torres VN, Williams EC, Ceballos RM, Donovan DM, Ornealas IJ.
Journal of Ethnicity in Substance Abuse 2022 (in press).

Neighborhood social environment change in late adolescence predicts substance use in emerging adulthood.
Perez LG, Tucker JS, Pedersen ER, Troxel WM, Rodriguez A, Firth CL, Seelam R, Shih RA, D’Amico EJ.
Health & Place 2022;75:102807

Negative attitudes about medications for opioid use disorder among criminal legal staff.
Moore KE, Siebert SL, Kromash R, Owens MD, Allen D.
Drug and Alcohol Dependence Reports 2022;3:100056.